GLP-1s and Alcohol: The JAMA Study That Changed Everything

Peer-Reviewed Publication

JAMA Psychiatry • January 2024

"GLP-1 Receptor Agonist Use and Risk of Alcohol Use Disorder"
Wang et al. • 83,825 patients analyzed

While reports of reduced alcohol cravings on Ozempic had been circulating for years, this study changed the conversation. Published in one of psychiatry's most prestigious journals, it provided hard data: GLP-1 medications are associated with dramatically lower rates of alcohol problems.

50%

lower AUD in patients with obesity

56%

lower AUD in patients with diabetes

What the Study Found

83,825

patients analyzed

12 mo

follow-up period

Real-world

health records data

Researchers compared patients starting semaglutide to matched patients starting other obesity or diabetes medications. They tracked who developed alcohol use disorder over the following year.

The results were striking:

In the obesity cohort: 50% lower risk of new AUD diagnosis
In the diabetes cohort: 56% lower risk of new AUD diagnosis
Effects held after controlling for age, sex, other medications, and comorbidities

Why This Study Matters

From Anecdote to Evidence

                Before this study, the connection between GLP-1s and reduced drinking was "interesting but unproven." After JAMA Psychiatry published these findings, it became a serious research priority. This is the difference between Reddit stories and peer-reviewed science.

How It Works

The Brain Science

Alcohol triggers dopamine release in the brain's reward centers—the same pathways that make food pleasurable. GLP-1 receptors are found throughout these regions:

Nucleus accumbens: Processes reward and pleasure
Ventral tegmental area: Where dopamine originates
Amygdala: Emotional responses to stimuli

By modulating dopamine signaling in these areas, GLP-1 medications appear to reduce alcohol's rewarding effects—making that drink less appealing.

What Patients Report

Real Experiences

"I used to have 2-3 glasses of wine every night. Now I'll pour one, take a sip, and forget about it. The desire just isn't there."

"Alcohol tastes different to me now. Less appealing. I went from a bottle of bourbon a week to maybe one drink a month."

"I didn't start Ozempic to quit drinking—I started it for weight loss. But the drinking stopped on its own. Best side effect ever."

Clinical Trials Now Underway

Based on these findings, randomized controlled trials are now testing GLP-1 medications specifically for alcohol use disorder. These will provide the definitive evidence needed for potential FDA approval.

Current trials include:

Semaglutide for AUD (multiple sites)
Tirzepatide for alcohol reduction
Combined GLP-1 + behavioral therapy approaches

Primary Source

Wang W, et al. "GLP-1 Receptor Agonist Use and Risk of Alcohol Use Disorder." JAMA Psychiatry. January 2024.

The Bottom Line

A major study in JAMA Psychiatry found that patients on semaglutide had 50-56% lower rates of alcohol use disorder compared to matched controls on other medications. This isn't anecdote—it's peer-reviewed research from one of medicine's most respected journals, analyzing nearly 84,000 patients. The mechanism (dopamine modulation in reward centers) is biologically plausible, and clinical trials are now underway. If you've noticed reduced interest in alcohol on your GLP-1 medication, science is catching up to what patients have been reporting for years.

Sources

Wang W, et al. JAMA Psychiatry. "GLP-1 Receptor Agonist Use and Risk of Alcohol Use Disorder." January 2024.
ClinicalTrials.gov. Active trials on GLP-1s for alcohol use disorder.
Mechanistic studies on GLP-1 receptors in brain reward pathways.